Latest Health News
Persevere Therapeutics Launches as a Clinical-Stage Oncology Company with a Novel Phase 1b/2a Agent and Announces First Close of Seed Financing
Chesterbrook, PA, March 03, 2026 (GLOBE NEWSWIRE) -- Persevere Therapeutics, Inc. (“Persevere”),…
Inteleos 2026 Leadership Elections Accelerate Vision for Global Healthcare
ROCKVILLE, Md., March 03, 2026 (GLOBE NEWSWIRE) -- Inteleos today announced its…
Psyence BioMed Announces Export of GMP-Manufactured Natural Psilocybin (NPX-5) to Australia for Ongoing Phase IIb Clinical Trial
NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq:…
RadNet, Inc. to Present at the Raymond James 47th Annual Institutional Investors Conference on Tuesday, March 3rd, 2026
March 02, 2026 13:16 ET | Source: RadNet, Inc. LOS ANGELES, March…
Smith+Nephew to feature leading rotator cuff repair portfolio including new Tendon Seam Repair System and REGENETEN Bioinductive Implant at AAOS 2026
Uniting the most advanced technologies for biomechanical repair and biological augmentation Smith+Nephew…
Pediatric Home Service Partners with Morgans to Expand Prescribed Pediatric Extended Care Services in Texas with New Center, Morgans Wonder Care
SAN ANTONIO, March 02, 2026 (GLOBE NEWSWIRE) -- Pediatric Home Service (PHS),…
Rhythm Pharmaceuticals Announces Additional Positive Data from Phase 3 TRANSCEND trial of Setmelanotide in Patients with Acquired Hypothalamic Obesity
-- -18.8% placebo-adjusted difference in BMI reduction achieved in all patients (N=142)…
Celldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar Profound Efficacy to First Exposure in Patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Further Demonstrating First-in-Class and Best-in-Disease
March 01, 2026 09:45 ET | Source: Celldex Therapeutics, Inc. - Late…
